Biocon Biologics Secures Global Rights to Hulio
The new agreement supersedes the existing collaboration agreement between Biocon Biologics and Fujifilm Kyowa Kirin Biologics (FKB) for biosimilar Adalimumab, under which Biocon Biologics only had commercialisation rights.
Biosimilars Business | 23/12/2025 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy